
Management of Metastatic Liver Tumors, An Issue of Surgical Oncology Clinics of North America
Series: The Clinics: Surgery; 30-1;
- Publisher's listprice EUR 83.99
-
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 13% (cc. 4 632 Ft off)
- Discounted price 30 996 Ft (29 520 Ft + 5% VAT)
35 628 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier
- Date of Publication 1 December 2020
- ISBN 9780323764490
- Binding Hardback
- No. of pages240 pages
- Size 228x152 mm
- Weight 500 g
- Language English 167
Categories
Long description:
This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Michael I. D'Angelica, is devoted to Management of Metastatic Liver Tumors. Dr. D'Angelica has assembled expert authors to review the following topics: Surgical management of liver metastases of colorectal cancer; Surgical management of liver metastases of breast cancer; Surgical management of liver metastases of neuroendocrine tumors; Surgical management of liver metastases of sarcoma (including GIST); Surgical management of liver metastases of gynecologic cancers; Surgical management of liver metastases of genitourinary cancers; Surgical management of liver metastases of uveal and dermal melanoma; Is there a role for locoregional therapies for non-colorectal GI malignancies?; Intra-arterial chemotherapy for liver metastases; External beam radiation for liver metastases; Isolated hepatic perfusion for liver metastases; Debate: Improvements in systemic therapies for liver metastases will soon render locoregional treatments obsolete; Debate: Improvements in systemic therapies for liver metastases will increase the role of locoregional treatments; and more!
More